896 related articles for article (PubMed ID: 26267412)
1. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.
Niwińska A; Murawska M; Pogoda K
Cancer; 2010 Sep; 116(18):4238-47. PubMed ID: 20549816
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
[TBL] [Abstract][Full Text] [Related]
5. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
6. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
Bartsch R; Rottenfusser A; Wenzel C; Dieckmann K; Pluschnig U; Altorjai G; Rudas M; Mader RM; Poetter R; Zielinski CC; Steger GG
J Neurooncol; 2007 Dec; 85(3):311-7. PubMed ID: 17557136
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Study on the Efficacy of Trastuzumab in HER2-Positive and Tamoxifen-Refractory Breast Cancer with Brain Metastasis.
Zhang C; Wang L; Wang L; Cui S
BioDrugs; 2016 Feb; 30(1):33-40. PubMed ID: 26792291
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
Lin NU; Freedman RA; Ramakrishna N; Younger J; Storniolo AM; Bellon JR; Come SE; Gelman RS; Harris GJ; Henderson MA; Macdonald SM; Mahadevan A; Eisenberg E; Ligibel JA; Mayer EL; Moy B; Eichler AF; Winer EP
Breast Cancer Res Treat; 2013 Nov; 142(2):405-14. PubMed ID: 24197661
[TBL] [Abstract][Full Text] [Related]
10. Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab.
Kaplan MA; Ertugrul H; Firat U; Kucukoner M; İnal A; Urakci Z; Pekkolay Z; Isikdogan A
Breast Cancer; 2015 Sep; 22(5):503-9. PubMed ID: 24385387
[TBL] [Abstract][Full Text] [Related]
11. Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis.
Pessina F; Navarria P; Cozzi L; Franceschini D; Tomatis S; Clerici E; Ascolese AM; DE Rose F; Bello L; Masci G; Santoro A; Scorsetti M
Anticancer Res; 2017 Dec; 37(12):7057-7062. PubMed ID: 29187495
[TBL] [Abstract][Full Text] [Related]
12. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK
Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445
[TBL] [Abstract][Full Text] [Related]
13. Pyrotinib combining with radiotherapy on breast cancer with brain metastasis.
Ma X; Li Y; Zhao Z; Li L; Gao C; Liu D; Li B; Zhao B
Exp Biol Med (Maywood); 2023 Jan; 248(2):106-116. PubMed ID: 36533572
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.
Park IH; Ro J; Lee KS; Nam BH; Kwon Y; Shin KH
Ann Oncol; 2009 Jan; 20(1):56-62. PubMed ID: 18664558
[TBL] [Abstract][Full Text] [Related]
16. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients.
Wolstenholme V; Hawkins M; Ashley S; Tait D; Ross G
Breast; 2008 Dec; 17(6):661-5. PubMed ID: 18571923
[TBL] [Abstract][Full Text] [Related]
17. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
Gori S; Inno A; Fiorio E; Foglietta J; Ferro A; Gulisano M; Pinotti G; Gubiotti M; Cavazzini MG; Turazza M; Duranti S; De Simone V; Iezzi L; Bisagni G; Spazzapan S; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Santini D; Fabi A; Garrone O; Frassoldati A; Amaducci L; Saracchini S; Evangelisti L; Barni S; Gamucci T; Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L
PLoS One; 2015; 10(9):e0136731. PubMed ID: 26340098
[TBL] [Abstract][Full Text] [Related]
18. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
Shawky H; Tawfik H
J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797
[TBL] [Abstract][Full Text] [Related]
19. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]